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Background: Systemic congestion is one of the mechanisms involved in acute decompensated 23 
heart failure (ADHF). Increased intraabdominal pressure (IAP), elicited by abdominal congestion, 24 
has been related to acute kidney injury and prognosis. Nonetheless, the link between diuretic 25 
response, surrogate markers of congestion and renal function remains poorly understood.  26 
Methods and results: We measured IAP in 43 patients from a non-interventional, exploratory, 27 
prospective, single center study carried out in patients admitted for ADHF. IAP was measured 28 
with an calibrated electronic manometer through a catheter inserted in the bladder. Normal IAP 29 
was defined as < 12 mmHg.  At baseline, median IAP was 15 mmHg, with a reduction over the 30 
next 72 hours to a median of 12 mmHg. A higher IAP at admission was associated with higher 31 
baseline blood urea (83 mg/dL [62 - 138] vs. 50 mg/dL [35 – 65]; p=0.007) and creatinine (1.30 32 
mg/dL vs 0.95 mg/dL; p=0.027), and with poorer diuretic response 72 hours after admission, 33 
either measured by diuresis (14.4 mL/mg vs. 21.6 mL/mg; [p = 0.005]) or natriuresis (1.2 34 
mEqNa/mg vs. 2.0 mEqNa/mg; [p = 0.008]). A higher incidence for one-year all-cause mortality 35 
(45.0% vs 16.7%; log-rank test = 0.041) was observed among those patients with IAP>12mmHg 36 
at 72 hours. 37 
Conclusions: In patients with ADHF, higher IAP at admission is associated with poorer baseline 38 
renal function and impaired diuretic response. The persistence of IAP at 72 hours above 12 mm 39 














During the last few years, the importance of systemic venous congestion in heart failure (HF) has 52 
received increasing attention[1–3]. Most patients admitted for acute decompensated heart failure 53 
(ADHF), show signs or symptoms of congestion[4,5], hence guidelines recommend its prompt 54 
detection and treatment to improve outcomes[6]. 55 
However, up to one third of the patients still have some degree of clinical congestion at 56 
discharge[7,8], a situation termed residual clinical congestion, which is directly associated with a 57 
worse prognosis[8–10]. Residual clinical congestion is potentially caused by many factors, such 58 
as diuretic resistance[11] or persistent redistribution of fluid in interstitial space[12], situations 59 
leading to an increase in readmissions and mortality due to HF in a short and long-term basis[9].  60 
Given the deleterious effect of residual clinical congestion and the limitations of physical 61 
examination for its assessment[13], new tools to evaluate congestion have been suggested. 62 
Biomarkers, such as carbohydrate antigen 125 (CA125)[14–16] or Bio-Adrenomedullin (Bio-63 
ADM)[17,18], have shown a good correlation with clinical congestion. Additionally, some 64 
ultrasonographic (US) techniques are useful in refining prognostic assessment in HF. Both 65 
diameter and degree of collapse of inferior cava vein (ICV) have been associated with 66 
prognosis[19], as well as the presence of B lines in lungs, which presence during ADHF or its 67 
persistence after diuretics, confers poorer prognosis[20–23]. Hence, a combined assessment of 68 
congestion, including clinical, biochemical and US measurements, have been recommended by 69 
the European Society of Cardiology (ESC) for decision making and guided therapy in patients 70 
with acute HF[24]. 71 
 Intrabdominal pressure (IAP) is another biological parameter of potential interest in HF 72 
since it is directly linked to central venous pressure (CVP) and abdominal congestion[25]. The 73 
American Society of Surgeons defined physiological IAP below 12 mm Hg, when a bladder 74 
catheter is used for this measurement [26–28]. In the context of HF, an increased IAP has been 75 
suggested as a leading mechanism underlying worsening of renal function (WRF) in ADHF 76 
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patients[25]. Mullens et al[29], showed changes in IAP correlated with serum creatinine in 77 
patients with HF and severely reduced left ventricular ejection fraction (LVEF). Abu-Saleh et 78 
al[30], demonstrated that increased IAP contributes to kidney dysfunction by using a HFrEF mice 79 
model. Nevertheless, there is no evidence about the interaction between IAP and markers of 80 
congestion (measured by physical examination, biomarkers or US), or about how IAP influences 81 
renal function and diuretic response in patients with mild reduced LVEF or even HFpEF. Patients 82 
admitted for ADHF at Internal Medicine wards have higher rates of comorbidities and/or 83 
HFpEF[31], what allows studying IAP in a different context never explored. 84 
 The PIA study (from Spanish for intra-abdominal pressure) was designed to examine 85 
relationships between IAP, systemic venous congestion and renal function impairment in the 86 
context of ADHF. The objectives of this study were: (1) quantify IAP, and its changes after 87 
diuretic therapy, in patients admitted for ADHF; (2) analyze the relationship between systemic 88 
congestion and IAP; (3) establish the relationship between IAP and the development of worsening 89 
renal function. 90 
Patients and methods 91 
The PIA (for its name in Spanish, Presión Intra Abdominal) study is an observational, non-92 
interventional, descriptive and prospective study, carried out at the Internal Medicine department 93 
of the Hospital Clínico Universitario “Lozano Blesa”, Zaragoza, Spain, in two different periods 94 
(January 2016 to July 2016 and May 2017 to May 2018).  Inclusion criteria were: 1) Patients 95 
older than 18 years with a diagnosis of ADHF, either “de novo” or decompensated chronic HF; 96 
2) NT-proBNP > 1000 pg / ml in the first 36 hours after admission; 3) Estimated glomerular 97 
filtration rate (eGFR) ≥ 20 ml / min / 1.72 m2 by Chronic Kidney Disease Epidemiology 98 
Collaboration (CKD-EPI-Creatinine formula) and 4) Written informed consent. Exclusion criteria 99 
were: 1) Admission to the intensive care unit. 2) Significant valve disease (severe aortic stenosis, 100 
severe mitral stenosis or mitral regurgitation); 3) Advanced COPD (spirometry with FEV1 <30%) 101 
and 4) ADHF due to arrhythmias (except atrial/flutter fibrillation). 5) Loop diuretic e.v. 102 
treatment ≥ 24 hours after admission to internal medicine ward. 103 
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 Systemic congestion was estimated by different methods, detailed below: 1) A clinical 104 
congestion score (CCS) previously described[9]. 2) Ultrasonographic measurement of diameter 105 
and collapse of IVC. 3) Bio-impedance vector analysis (BiVA) of body water content and 4) 106 
Blood biomarkers of congestion (NT-ProBNP and CA125).  107 
Baseline moment was defined as the first 24 hours after being admitted at the 108 
Internal Medicine ward. 109 
 A 2D echocardiography performed between 6 months before admission and one month 110 
after discharge was required. Left ventricular ejection fraction (LVEF) was calculated by Simpson 111 
biplane method. 112 
 The study complied with the fundamental guidelines of the Helsinki International 113 
Declaration and was approved by the Clinical Research Ethics Committee of Aragón (CEICA, 114 
Ref. C.P.-C.I. PI15 / 0227 to date September 9, 2015). Written informed consent was obtained 115 
from all patients. 116 
Intraabdominal pressure measurement 117 
IAP was calculated by an indirect method, according to Cheatham ML et al [26,27]. Briefly, the 118 
method consisted in placing a Foley catheter into the bladder, filled with 50 cc of saline solution, 119 
connected to a digital manometer (DM2Plus®,Fluke Biomedical, units: mmHg)[27]. IAP values 120 
obtained through this procedure has been shown to correlate adequately with actual IAP[28] and 121 
had been validated by the American Society of Surgeons[26]. Measurements were taken at 24, 48 122 
and 72 hours after admission, always by the same researcher, with a minimum interval of 2 hours 123 
after food intake and with the patient placed in supine position. All patients signed a specific 124 
informed consent to perform this procedure in case a bladder catheter had not been placed at the 125 
Emergency Ward. Four urinary catheters had to be removed; three after 48 hours, due to revoked 126 
consent and one after 24 hours because of an uncomplicated urinary tract infection. 127 
Diuretic response and worsening renal function 128 
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During the first 72 hours after admission, an exhaustive analysis of renal function was performed, 129 
including 24-, 48- and 72-hours total diuresis and urine analysis (all patients had bladder 130 
catheterization for IAP measurement). Blood analyses were performed at baseline and before 131 
discharge to evaluate renal function. In addition, cumulative dose of intra venous (i.v.) furosemide 132 
(mg) was registered at 24, 48 and 72 hours.  133 
 For diuretic response (DR), three formulae based on weight, diuresis or natriuresis, 134 
respectively, were used: 1) Δ weight kg at 72 h/40 mg furosemide[11]. 2) Urine output during the 135 
first 72 h (Total diuresis at 72 h [mL]/Total intravenous furosemide [mg] 72 hours) and 3) Total 136 
urinary sodium at 72 h (mEq/L)/Total intravenous furosemide (mg) 72 h. 137 
Laboratory samples 138 
Blood samples were withdrawn at admission and discharge. Serum biomarkers measured were 139 
NT-ProBNP (Modular Analytics Analyzer E601 Roche diagnostics GmbH, Mannheim, 140 
Germany), Cystatin C (Latex N Test, with BN II dade Behring GmbH, Marburg, Germany) and 141 
CA125 (Roche Diagnostics GmbH, Mannheim, Germany).  142 
 Urine samples were also collected daily, during the first 72 hours and assessed for urinary 143 
Kidney Injury Molecule 1 (KIM-1) concentrations following manufacturer instructions (kit 144 
DKM100; R&D Systems Europe, UK). 145 
Analysis of inferior cava vein 146 
During the first 72 hours from inclusion, measurements of the diameter of IVC and the 147 
degree of inspiratory collapse were taken daily in long axis. The LOGIQ F6 (General 148 
Electrics Healthcare ©) and the G3S 1.7-3.8 MHz transducer probes were used for this 149 
purpose. IVC was assessed, with patient in supine position and with the least elevation of 150 
the upper body. IVC diameter was calculated from the cross sections of IVC by M-mode in 151 
both inspiration and expiration using the formula: 1 – ([IVC diameter inspiration/IVC 152 
diameter expiration] x 100). 153 
Bio-impedance vector analysis  154 
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Bio-impedance vector analysis (BiVA) was performed using an EFG-electrofluidgraph 155 
(Akern©). Two electrodes were placed on the ventral side of the hand and foot of the same side 156 
of the body, daily during the first three days after admission and 24 h. prior to discharge.  Body 157 
composition values were calculated based on size and weight determined daily at 24, 48 and 72 158 
h. The variables obtained by this technique were total body water (TBW), total extracellular water 159 
(TEW) and body mass index (BMI). 160 
Clinical congestion score 161 
A previously validated CCS[8,9] was calculated at admission and discharge. The score included 162 
orthopnea, the presence of edema and jugular vein distension (JVD). The weight of each variable 163 
was distributed as follows: orthopnea (0 to 3), peripheral edema (0 to 3) and JVD (0 to 2). Patients 164 
with a CCS ≥ 1 at discharge were considered as having “residual congestion”. 165 
Outcomes 166 
Time-to event, all-cause mortality and HF-readmissions were registered. To the purpose of the 167 
survival analysis, follow-up started after discharge. Outcomes were identified by reviewing 168 
medical records of each included patient. Occurrence of WRF during hospitalization was 169 
surveyed as an additional outcome. 170 
Statistical Analysis 171 
Continuous variables were expressed by mean or median depending on the normality of each 172 
variable. Categorical variables were expressed as a percentage. The t-Student’s or ANOVA test 173 
was used for comparisons between continuous and normally distributed variables. Variables not 174 
normally distributed were compared with U-Mann Whitney or Kruskal-Wallis test. For 175 
categorical variables comparison, the chi-squared test was used. Correlation analysis was 176 
performed using the Pearson or Spearman test, according to normality. 177 
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 The confidence intervals included were 95% (CI95%), establishing the statistical 178 
significance for p values lower than 0.05. Statistical analysis was performed with the Statistical 179 




Baseline characteristics 184 
A total of 43 patients completed the PIA study (Flow chart is shown in Supplementary figure 185 
1). Mean age was 80.1 ± 8.4 years, with a higher proportion of females (62.8%) and patients with 186 
a previous admission for ADHF (60.5%). The most prevalent comorbidities were arterial 187 
hypertension (83.7%), atrial fibrillation/flutter (67.4%), hypercholesterolemia (51.2%), diabetes 188 
mellitus (39.5%) and chronic kidney disease (CKD) (39.5%) (Table S1, in supplementary 189 
material). 190 
Intrabdominal pressure analysis  191 
A high proportion of patients (33 patients [76.7%]) showed increased IAP (≥ 12 mmHg) at 192 
baseline. Baseline median IAP was 15.0 (11.0 – 17.0). IAP significantly declined at 72 hours 193 
(12.0 [10.0 – 15.0]; p = < 0.001). At 72 hours, IAP remained elevated (> 12 mmHg) in 19 patients 194 
(48.7%). IAP time-line changes for each individual are shown in Figure 1. 195 
Intrabdominal pressure at baseline (Table 1). 196 
Patients with baseline IPA above 12 mm Hg, showed higher prevalence of CKD (48.5% vs. 197 
10.0%: p=0.029), higher concentrations of baseline serum creatinine (1.30 mg/dL vs. 0.95 mg/dL; 198 
p=0.007) and uric acid (8.1 mg/dL vs. 5.2 mg/dL; p=0.002), as well as larger IVC diameter at 199 
admission (19.7 mm vs. 13.2 mm; p=0.013).   200 
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The incidence of WRF and signs of tubular damage (urine concentrations of KIM-1) were 201 
similar in both groups, regardless baseline IAP. 202 
Intrabdominal pressure after 72 hours of admission (Table 2). 203 
Patients with a remaining elevated IAP (>12 mm Hg) 72 h after admission, had received higher 204 
doses of i.v. furosemide during that period of time  (190 mg [140 – 320] vs. 130 mg [97.5 – 205 
160.0]; p=0.001) and their diuretic response was impaired, either measured by total diuresis (14.4 206 
mL/mg [9.1 – 23.8] vs. 21.6 mL/mg [14.3 – 29.9]; p= 0.050) or natriuresis (1.2 mEq/mg [0.5 -207 
1.8] vs. 2.0 mEq/mg [1.7 – 2.5]; p=0.008). The group of patients with persistently high IAP at 72 208 
h, showed a larger diameter of IVC at any measurement during hospitalization: baseline (20.2 209 
mm vs. 15.0 mm; p=0.046), 72 hours (17.0 mm vs. 16.0 mm; p=0.028) and discharge (17.1 mm 210 
vs. 12.4 mm; p=0.032). Of note, there were no differences in right ventricle systolic function, 211 
as expressed by TAPSE, nor in PASP, depending on the level of remaining IAP at 72 h. 212 
Furthermore, the group with remaining high IAP at 72 h had a larger volume of total body 213 
water (41.6 L [40.9 – 43.5] vs. 35.0 L [31.5-47.0]; p=0.001) and total extracellular water (22.4 L 214 
[21.1 – 30.6] vs. 20.8 L [15.0 – 28.0]; p=0.005) at 72 h. 215 
Intrabdominal pressure and renal function 216 
As compared to patients with normal renal function at admission, those with impaired function 217 
(eGFR < 60 mL/min/1.73m2 [CKD-EPI-Creatinine]) had lower BMI (27.9 kg/m2 vs. 32.0 kg/m2; 218 
p=0.005) and had been treated in a lower proportion with mineralocorticoid receptor antagonists 219 
(9.2% vs 15.4%; p = 0.034). Hemoglobin (11.5 g/L vs. 12.3 g/L; p=0.031) and bicarbonate 220 
concentrations (22.9 vs. 26.1 mmol/L; p=0.018) were lower, whilst CA125 (49.3U/mL vs. 36.1 221 
U/mL; p= 0.028) was significantly higher among patients with renal dysfunction. 222 
There were no differences in IAP at baseline (15.6 mm Hg vs. 14.9 mm Hg; p=0.613) or 223 
at 72 hours (12.5 mm Hg vs. 12.1 mm Hg; p=0.791), in IVC diameter and its degree of collapse, 224 
and in total body water and total extracellular water, with regard to admission eGFR (A complete 225 
data set is shown in Table S2, supplementary material).  226 
Con formato: Fuente: Negrita
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Intraabdominal pressure and outcomes 227 
During follow-up, 12 deaths (29.3%) and 26 readmissions (61.9%) were registered. One-year all-228 
cause mortality was significantly higher among those patients whose IAP after 72 hours of 229 
admission, remained elevated (45.0 % vs. 16.7%; Log-rank test = 0.041) (Figure 2). This group 230 
also had a longer hospital stay (9.0 days vs. 5.5 days; p=0.005).  231 
Seven patients (17.9%) developed WRF during admission. This group had higher 232 
concentrations at admission of NT-proBNP (8929 pg/mL vs. 3092 pg/mL; p=0.004), creatinine 233 
(1.67 mg/dL vs. 1.03 mg/dL; p=0.017) and cystatin C (2.17 U/mL vs. 1.51 U/mL; p=0.013). 234 
Baseline water content (total body water and total extracellular water), IVC diameter, its degree 235 
of collapse and IAP (baseline and at 72 hours) did not differ between patients with or without 236 
WRF (a complete data set is shown in Table S3, supplementary material). 237 
Discussion 238 
Our study showed that elevated IAP was present in the majority of patients who were hospitalized 239 
for ADHF. Increased IAP levels at admission were associated with poorer baseline renal function 240 
and a poorer diuretic response. A higher all-cause mortality was observed in patients with 241 
persistently increased IAP after 72 hours. To our knowledge, there are no previous studies 242 
simultaneously addressing systemic venous congestion, diuretic response and IAP. Our findings 243 
may contribute to a better understanding on the role of congestion and IAP in the pathophysiology 244 
of ADHF.  245 
IAP as a surrogate marker of systemic venous congestion 246 
According to the criteria of the American Society of Surgeons, that established 12 mm Hg as the 247 
cut-off value of normalcy for IAP[27,32], we found that roughly two thirds of ADHF patients in 248 
our cohort presented with elevated IAP at admission. More interestingly, in half of them, IAP 249 
remained increased 72 h later, after i.v. diuretics had been administered and signs and symptoms 250 
of congestion had relieved.  251 
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 Most of the surrogate markers of congestion (IVC diameter, CA125 and BiVA) were 252 
higher in the group of patients with elevated IAP as compared to those with normal values. Of 253 
note, admission IAP was positively correlated to the diameter of IVC, body water content by 254 
BiVA and CCS; even more, the correlation was still significant for IVC and BiVA 72 h after 255 
admission. This time-line change reflects a parallel pattern of behavior of systemic venous 256 
congestion and IAP, lending experimental support to the notion that IAP is an additional surrogate 257 
marker of systemic congestion.  258 
 The relationship between IAP and systemic congestion should be interpreted in the 259 
context of water and salt retention and volume expansion taking place in HF. Altogether, those 260 
alterations give rise to an increase in CVP reflected through the enlargement of IVC diameter and 261 
physical signs of congestion. Extracellular volume expansion is partially compensated by a 262 
redistribution of volemia, including a shift to the splanchnic bed that accounts for the increase in 263 
IAP, which can be easily measured through a urine catheter. The absence of differences in 264 
TAPSE and PSAP regarding the levels of remaining IAP at 72 h. may partly be explained 265 
by the high proportion of patients with HFpEF in our cohort. Nonetheless, we think that it 266 
also points to the importance of the role of peripheral vascular bed, specially the splacnic 267 
venous territory, in the pathophysiology of decompensations of HF. 268 
 Our results suggest that quantification of IAP through a simple maneuver, such as the 269 
insertion of a urine catheter, provides an objective measure of the degree of systemic congestion 270 
and their changes under diuretic therapy. Although further studies are required, it is plausible to 271 
think that measuring IAP can be especially useful to guide diuretic therapy during the early phase 272 
of admission, especially in patients in whom physical examination is more difficult due to obesity 273 
or comorbidities.  274 
Intrabdominal pressure and renal function 275 
The interest on the relationships between IAP and cardiorenal syndrome in ADHF is recent, and 276 
the evidence scarce[25]. It is known that IAP correlates with changes in serum creatinine 277 
Comentado [UdMO1]: añadir la referencia al trabajo de 
Balmain 
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concentrations in patients with cardiogenic shock and LVEF below 20%[29]. In a recent primary 278 
study[30], based on a HFrEF mice model, IAP has been correlated with kidney dysfunction in 279 
both chronic heart failure and myocardial infarction models. However, these results[29,30] do not 280 
prove a causal relationship and probably cannot  be extrapolated to patients with other causes of 281 
acute HF or with preserved LVEF. 282 
 Damman et al[33], found a narrow relationship between CVP and renal function 283 
impairment during ADHF. Furthermore, several subanalyses of large clinical trials, have shown 284 
residual clinical congestion and WRF to be related, conferring to these patients worse 285 
prognosis[34–36]. These results reinforce the hypothesis of a link between systemic congestion 286 
and renal dysfunction in ADHF.  287 
In our cohort, renal function was poorer in patients with an admission IAP above normal 288 
values. These patients showed higher prevalence of previous CKD and concentrations of blood 289 
urea, creatinine and cystatin C significantly higher at admission. Surprisingly, we were not able 290 
to find any relationship between IAP, either at admission or after 72 h, and worsening renal 291 
function. Our data, hence, do not support a pathophysiological link between IAP and renal 292 
dysfunction. We could not find differences in IAP in our population, either at baseline or at 72 h, 293 
depending on whether admission eGFR was below or above 60 mL/min/1.73 m2 (Table S4, 294 
supplementary material),. Moreover, the occurrence of WRF did not differ between patients with 295 
normal or elevated IAP, either at admission or at 72 h (Table S3, supplementary material). The 296 
most plausible explanation is that the increase in IAP is the consequence of an insufficient diuretic 297 
response leading to a higher degree of remaining congestion, which in turn impairs renal 298 
function29,30. In this context, IAP appears merely as a surrogate marker of systemic congestion, 299 
the true protagonist in cardiorenal interactions during decompensations. As a matter of fact, the 300 
persistence of high IAP at 72 h was still associated to a lower response to loop diuretics, despite 301 
the higher doses of i.v. diuretics accumulated in this group.  302 
Diuretic resistance is a common observation in congestive ADHF[11,37,38]. As a 303 
surrogate marker for congestion, persistent elevation of IAP after diuretic therapy indicates a 304 
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higher degree of remaining systemic congestion, as indicated for concomitant persistence of 305 
increased IVC diameter and body water content (Table 3). Current evidence[24,39,40] suggests 306 
diuretic response is affected by congestion itself, but the mechanisms linking diuretic resistance 307 
to congestion are unknown and deserve further investigation.  308 
Prognostic significance of elevated Intrabdominal pressure 309 
Baseline (admission) IAP had no impact on prognosis; either in one-year all-cause mortality, or 310 
in HF-readmissions, nor on the incidence of WRF. However, a higher incidence of one-year all-311 
cause mortality was observed among patients with persistent IAP above normal levels at 72h. 312 
These results could be explained if we interpret IAP as a surrogate marker of congestion (Table 313 
3). Several studies have shown the prognostic importance of residual congestion and diuretic 314 
response during the early phase after admission. Valente et al.[41], found that diuretic response 315 
(defined as negative ∆ weight kg/40 mg furosemide) was predictive of death and readmissions 316 
for HF in PROTECT[42] a study designed to assess the efficacy of rolofylline on treating 317 
congestion and renal function in ADHF. 318 
 To the best of our knowledge, our study is the first showing a higher mortality in patients 319 
with persistently elevated IAP after intensive diuretic therapy (first 72 hours).  320 
Intraabdominal pressure, residual congestion and diuretic response. 321 
 A comprehensive view of our results reflects a rather complex relationship between IAP, water 322 
content and diuretic response that eventually result in decongestion. If our interpretation is correct, 323 
IAP is merely a marker of congestion without pathophysiological relation to the development of 324 
WRF or death. The persistence of high IAP accounts for residual congestion, a clinical fact that 325 
has been consistently linked to increases in mortality[8,43]. Changes in water content by BiVA 326 
were similar irrespective of IAP. Nonetheless, the dose of diuretics was much higher in the high 327 
IAP group, reflecting the impairment of diuretic response probably mediated by systemic 328 
congestion. If this interpretation is correct, the key to achieve an adequate decongestion during 329 
ADHF relies on the kidneys themselves. Probably, diuretic response during ADHF is the result 330 
14 
 
of previous renal function and i.v. diuretic titration, all of them dependent of local hemodynamic 331 
factors regulated by renin-angiotensin system, natriuretic peptides and others such as adenosine. 332 
A better understanding of  cardio-renal interactions and new diuretic strategies —including the 333 
addition of new decongestive therapies, such as sodium-glucose linked transporter 334 
inhibitors(SLGT2i)[44]— will allow clinicians to improve outcomes in ADHF by targeting 335 
systemic venous congestion.  336 
According to our results, the measurement of IAP during the early phase of admission 337 
may be of clinical interest to, by predicting the risk of residual congestion, implement optimal 338 
strategies to achieve a proper decongestion before discharge. There are several practical 339 
advantages of measuring IAP. First, the simplicity of its measurement; second, the objective 340 
threshold of normality; third, the prognostic yielded by IAP; and fourth, the possibility of 341 
monitoring the early changes in congestion occurring immediately after admission. Other proven 342 
useful biomarkers of congestion are rather variable, such as NT-proBNP[45,46],  or lack of a clear 343 
cut-off for interpretation, as happens with CA125[47,48], and their time-line changes cannot be 344 
discriminated over a few days, thus not being useful to monitor the prompt and quick variations 345 
in the degree of congestion early after admission[13]. 346 
To summarize, we propose that IAP is a surrogate marker of systemic congestion, 347 
independent of baseline renal function and its persistence at 72 h, after intensive diuretic 348 
treatment, has negative prognostic implications. 349 
5. Limitations 350 
The study has been carried out in a single center so its results cannot be generalizable. The sample 351 
size is small, although the systematic approach, the wide range of the procedures used to measure 352 
congestion, as well as the rigor in its execution, mitigate, at least in part, this limitation. The 353 
utility of IVC diameter to assess right atrial pressure could be limited by increased 354 
intraabdominal pressure and the presence of ascites (the grade of ascites was not registered). 355 
Finally, the pathophysiological mechanisms analyzed in this study are not well defined, so it can 356 
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be considered a pioneering study. More studies are needed to better understand the link between 357 
IAP, systemic congestion and diuretic response. Probably, a larger study, assessing the 358 
effectiveness of guiding diuretic treatment through intra-abdominal pressure would be interesting 359 
to clarify the usefulness of this measurement during acute heart failure admission.  360 
 361 
 362 
6. Conclusions 363 
The great majority of patients who were hospitalized for ADHF had elevated intra-abdominal 364 
pressure. A significant correlation was observed between baseline IAP, 72h IAP and surrogate 365 
markers of congestion (composite CCS, IVC and BiVA). Increased IAP at baseline was associated 366 
with poorer renal function and a poorer diuretic response. Patients with elevated IAP at 72 hours 367 
were hospitalized for a longer stay and showed  higher rates for all-cause mortality.  368 
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Table 1:  Baseline clinical characteristics according to normal (< 12 mmHg) or elevated IAP (≥ 12 mm Hg) at admission. 
Variable Normal IAP Elevated IAP p-value 
N (%) 10 (23.3) 33 (76.7)  
Age (years) 82.0 ± 8.5 79.6 ± 8.4 0.437 
Female (n[%]) 8 (80.0) 19 (57.6) 0.199 
BMI (Kg/m2) 28.7 ± 7.1 30.6 ± 5.9 0.408 
SBP (mm Hg) 142.9 ± 22.8 137.6 ± 21.8 0.451 
DBP (mm Hg) 84.9 ± 12.3 77.1 ± 13.0 0.099 
HR (b.p.m) 82.6 ± 12.3 80.1 ± 17.5 0.744 
LVEF (%) 55.9 ± 14.7 45.7 ± 14.5 0.064 
TAPSE (mm) 22.0 ± 2.1 19.4 ± 5.6 0.338 
PASP (mmHg) 42.8 ± 16.4 46.9 ±18.1 0.626 
Length of stay (days) 5.5 (4.7 – 8.5) 9.0 (8.0 – 16.5) 0.005 
HF treatment (n[%])    
• ACEi/ARBs 8 (80.0) 23 (69.7) 0.525 
• B-blockers 4 (40.0) 19 (57.6) 0.329 
• MRA 1 (10.0) 7 (21.2) 0.425 
• Loop diuretic 6 (60.0) 25 (75.8) 0.330 
Commorbidities (n[%]):    
• HF admissions 7 (70.0) 19 (57.6) 0.481 
• Hypertension 7 (70.0) 29 (87.9) 0.180 
• Dyslipemia 5 (50.0) 17 (51.5) 0.933 
• Chronic coronary disease 2 (20.0) 12 (36.4) 0.333 
• Diabetes mellitus 3 (30.0) 14 (42.4) 0.481 
• Atrial fibrillation/flutter 7 (70.0) 22 (66.7) 0.844 
• COPD/Asthma 1 (16.7) 5 (15.2) 0.680 
• Chronic kidney disease 1 (10.0) 16 (48.5) 0.029 
• PCI 2 (4.7) 14 (42.4) 0.199 
• Pacemaker 2 (20.0) 3 (9.1) 0.346 
ACEi: Angiotensin-converting-enzyme inhibitor; ARBs: Angiotensine recepctor blockers; BMI: Body mass index; b.p.m.: 
beats per minute; COPD: Chronic obstructive pulmonary disease; DBP: Diastolic blood pressure; HF: Heart failure; HR: 
Heart rate; LVEF: Left ventricular ejection fraction; MRA: Mineraloid receptor antagonists; PASP:  Pulmonary artery 
systolic pressure; PCI: Percutaneous coronary intervention. SBP: Systolic blood pressure; TAPSE:  Tricuspid annular 





Table 1 (cont.):   Baseline clinical characteristics according to normal (< 12 mmHg) or elevated IAP (≥ 12 mm Hg) at admission. 
Variable Normal IAP Elevated IAP p-value 
N (%) 10 (23.3) 33 (76.7)  
Renal function data and diuretic response    
• Urea at admission (mg/dL)  40 (31 – 59) 58 (44 – 92) 0.056 
• Urea at discharge (mg/dL) 50 (35 – 65) 83 (62 – 38) 0.007 
• Creatinine at admission (mg/dL) 0.95 ± 0.31 1.30 ± 0.56 0.027 
• Creatinine at discharge (mg/dL) 0.87 (0.68 – 1.18) 1.18 (0.96 – 1.99) 0.060 
• Cystatin-C at admission (mg/dL) 1.41 ± 0.45 1.73 ± 0.61 0.235 
• Cystatin-C at discharge (mg/dL) 1.60 ± 0.71 1.83 ± 0.76 0.592 
• eGFR at admission (CKD-EPI- Creatinine) 58.0 (53.8 – 85.5) 48.5 (30.5 – 74.9) 0.196 
• eGFR at discharge (CKD-EPI- Creatinine) 63.6 (51.3 – 85.5) 50.0 (28.3 – 62.8) 0.019 
• Uric acid (mg/dL) 5.2 ± 2.4 8.1 ± 2.3 0.002 
• Potassium (mEq/L) 4.1 ± 0.8 4.3 ± 0.5 0.955 
• KIM-1 at admission (ng/mL) 367.7 (123.2 – 663.4) 287.1 (130.0 – 
589.0) 
0.818 
WRF at discharge (n[%])    
• Defined as increase in creatinine ≥ 0.3 mg/dL 0 (0.0) 2 (6.9) 0.394 
Surrogate congestion markers    
• CCS at admission (points) 4.5 (4.0 – 5.7) 6.0 (5.0 – 7.0) 0.080 
• IAP at 72 hours (mmHg) 9.8 ± 3.5 13.1 ± 4.1 0.030 
• IAP decrease (%) -0.5 (-1.5 – 0.5) -3.0 (-6.0 - -1.0) 0.015 
• IVC diameter at admission (mm) 13.2 (11.1 – 17.7) 19.7 (16.9 – 25.4) 0.013 
• IVC diameter at 72 hours (mm) 18.2 (14.3 – 20.2) 19.5 (17.1 – 24.2) 0.082 
• NT-proBNP at admission (pg/mL) 5767 (2133 – 7442) 3404 (2312 – 8926) 0.530 
• CA125 at admission (U/mL) 39.4 (13.9 – 62.7) 43.6 (28.8 – 146.3) 0.078 
• TBW at admission (L) 39.6 ± 6.4 43.1 ± 13.2 0.059 
• TBW at 72 h (L) 33.5 ± 3.9 44.5 ± 12.5 0.044 
• TEW at admission (L) 22.2 ± 9.5 25.0 ± 7.2 0.041 
• TEW at 72 h (L) 22.0 ± 8.9 24.4 ± 5.9 0.036 
CA 125: Carbohydrate antigen 125; CCS: Composite congestion score; eGFR: Estimated-glomerular filtration rate; IAP: Intraabdominal Pressure; 
IVC: Inferior vena cava; KIM-1: Kidney injury molecule 1; NT-proBNP: amino terminal fragment of brain natriuretic peptide; TBW: Total body 





Table 2:  Baseline characteristics according to normal (< 12 mmHg) or elevated IAP (≥ 12 mm Hg) at 
72 hours 
 
Variable Normal IAP Elevated IAP p-value 
N (%) 19 (48.7) 20 (51.3)  
Age (years) 83.0 (77.0 – 88.0) 81.5 (77.7 – 84.0) 0.304 
Female (n[%]) 13 (68.4%) 11 (55.0) 0.389 
BMI (Kgs/m2) 28.8 ± 6.6 31.4 ± 5.9 0.214 
SBP (mmHg) 140.5 ± 20.5 139.7 ± 20.3 0.894 
DBP (mmHg) 80.1 ± 14.0 80.1 ± 10.9 0.998 
HR (b.p.m) 85.1 ± 17.4 76.9 ± 13.5 0.109 
LVEF (%) 44.6 ± 15.5 38.4 ± 15.8 0.446 
TAPSE (mm) 20.1 ± 3.4 19.7 ± 6.1 0.767 
PASP (mmHg) 47.2 ± 20.9 43.1 ± 19.3 0.693 
Lenght of stay (days) 8 (5 – 10) 10 (6 – 19) 0.189 
HF treatment (n[%])    
• ACEi/ARBs 14 (73.7) 14 (73.7) 0.798 
• B-blockers 9 (47.4) 13 (65.0) 0.267 
• MRB 5 (26.3) 1 (5.0) 0.065 
• Loop diuretic 15 (78.9%) 14 (70.0) 0.522 
Comorbidities (n[%]):    
• HF admissions 11 (57.9) 13 (65.0) 0.648 
• Hypertension 16 (84.2) 6 (80.0) 0.732 
• Dislipemia 9 (47.4) 12 (60.0) 0.429 
• Chronic 
coronary disease 
6 (31.6) 7 (35.0) 0.821 
• Diabetes mellitus 7 (36.8) 10 (50.0) 0.408 
• Atrial 
fibrillation/flutter 
15 (78.9) 11 (55.0) 0.113 
• COPD/Asthma 3 (15.8) 3 (15.0) 0.946 
• Chronic kidney 
disease 
6 (31.6) 10 (50.0) 0.242 
• PCI 6 (31.6) 9 (45.0) 0.389 
• Pacemaker 3 (15.8) 1 (5.0) 0.267 
ACEi: Angiotensin-converting-enzyme inhibitor; ARBs: Angiotensine recepctor blockers; BMI: Body 
mass index; b.p.m.: beats per minute; COPD: Chronic obstructive pulmonary disease; DBP: Diastolic 
blood pressure;  HF: Heart failure ; HR: Heart rate; LVEF: Left ventricular ejection fraction; MRB: 
Mineraloid receptor blockers;  PASP:  Pulmonary artery systolic pressure; PCI: Percutaneous coronary 
intervention. SBP: Systolic blood pressure;  TAPSE:  Tricuspid annular plane systolic excursion 
 
Table 2 (cont.):   Baseline characteristics according to normal (< 12 mmHg) or elevated IAP (≥ 12 mm Hg) at 72 hours 
 
Variable Normal IAP Elevated IAP p-value 
Total (n[%]) 19 (44,2) 24 (55.8)  
WRF at discharge (n[%])    
• Defined as increase in creatinine ≥ 0.3 mg/dL 1 (5.6) 1 (5.9) 0.967 
Biomarkers    
• NT-proBNP at admission (pg/mL) 5767 (2476 – 7442) 3331 (2156 – 13264) 0.815 
• NT-proBNP at discharge (pg/mL) 2166 (1817 – 3616) 2552 (1065 – 6570) 0.925 
• Cystatin-C at admission (mg/dL) 1.53 (1.28 – 2.11) 1.51 (1.26 – 1.94) 0.275 
• Cystatin-C at discharge (mg/dL) 1.46 (1.39 – 2.33) 1.48 (1.28 – 2.15) 0.980 
• CA125 at admission (U/mL) 43.6 (30.7 – 128.1) 39.9 (16.2 – 103.4) 0.692 
• CA125 at discharge (U/mL) 38.7 (24.0 – 130.2) 50.9 (22.1 – 182.7) 0.963 
• KIM-1 at admission (ng/mL) 240.1 (129.7 – 626.5) 406.4 (129.4 – 566.1) 0.555 
Diuretic response (during first 72 h after admission)    
• Total natriuresis (mEq/mL) 91.5 ± 22.6 81.3 ± 27.4 0.320 
• Total i.v. loop diuretic dose (mg) 130 (97.5 – 160.0) 190.0 (140.0 – 320.0) 0.001 
• Diuretic response by weight (∆weight at 72 
hours/ 40mg e.v. furosemide 
-0.52 (-0.98 - -0.01) -0.22 (-0.64 – 0.0) 0.180 
• Diuretic response diuresis (mL urine /mg 
furosemide i.v.) 
21.6 (14.3 – 29.9) 14.4 (9.1 – 23.8) 0.050 
• Diuretic response natriuresis (mEq Na / mg 
furosemide i.v.) 
2.0 (1.7 – 2.5) 1.2 (0.5 – 1.8) 0.008 
Congestion surrogate markers    
• IVC diameter at admission (mm) 15.0 ± 3.5 20.2 ± 4.6 0.046 
• IVC diameter at 72 h (mm) 16.0 ± 4.4 17.0 ± 2.5 0.028 
• IVC diameter at discharge (mm) 12.4 ± 3.3 17.1 ± 3.9 0.032 
• TBW at admission (L) 36.4 (30.9 – 49.3) 42.4 (39.1 -  43.5) 0.054 
• TBW at 72 h (L) 35.0 (31.5 – 47.0) 41.6 (40.9 – 43.5) 0.001 
• TBW at discharge (L) 34.2 (31.9 – 40.1) 39.9 (35.5 – 41.5) 0.371 
• TEW at admission (L) 18.0 (15.0 – 31.1) 28.1 (20.1 – 33.9) 0.002 
• TEW at 72 h (L) 20.8 (15.0 – 28.0) 22.4 (21.1 – 30.6) 0.005 
• TEW at discharge (L) 19.6 (16.0 – 32.1) 24.5 (20.3 – 29.6) 0.569 
CA 125: Carbohydrate antigen 125; CCS: Composite congestion score; e-GFR: estimated Glomerular filtration rate; IAP: Intraabdominal Pressure; 
I.v.:  intravenous; IVC: Inferior vena cava; KIM-1: Kidney injury molecule 1; NT-proBNP: amino terminal fragment of brain natriuretic peptide 
TBW: Total body water; TEW: Total Extracellular water; WRF: Worsening renal function. 





CCS: Composite congestion score; IVC: Inferior vena cava; LVEF: Left ventricular ejection fraction; 
TBW: Total body water; TEW: Total extracellular water.  














LVEF (%)* -0.299 0.068 -0.163 0.351 
CCS at baseline (points)* 0.451 0.006   
B Kerley lines at baseline (total 
number)* 
0.249 0.276   
B Kerley lines at 72 hs (total 
number)* 
  0.425 0.130 
TBW at baseline (L)* 0.422 0.005   
TEW at baseline (L)* 0.438 0.004   
TBW at 72 hours(L)*   0.363 0.030 
TEW at 72 hours (L)*   0.210 0.219 
IVC diameter at baseline (mm)* 0.553 < 0.001   
IVC diameter at 72 hs (mm)*   0.399 0.014 
Supplementary figure 1: Flow chart of PIA study. 
200 initially scrutinized 
73 denied informed consent 
30 presented with advanced cognitive 
decline 
29 presented with advanced impaired renal 
function 
3 other causes 
65 initially included 
22 patients rejected bladder 
catheter 
43 patients finally included 
Table S1:  Baseline clinical characteristics  
N (%) 43 (100.0%) 
Age (years) 80.1 ± 8.4 
Female (n[%]) 27 (62.8) 
BMI (Kg/m2) 29.6 (27.0 – 34.7) 
SBP (mm Hg) 138.2 ± 22.1 
DBP (mm Hg) 78.9 ± 13.0 
HR (b.p.m) 81.0 ± 16.3 
LVEF (%) 48.4 ± 15.0 
TAPSE (mm) 19.9 ± 5.2 
PASP (mmHg) 45.9 ± 17.5 
Length of stay (days) 9 (6 – 15) 
HF treatment (n[%])  
• ACEi/ARBs 31 (72.1) 
• B-blockers 23 (53.5) 
• MRA 8 (18.6) 
• Loop diuretic 31 (72.1) 
Commorbidities (n[%]):  
• HF admissions 26 (60.5) 
• Hypertension 36 (83.7) 
• Dyslipemia 22 (51.2) 
• Chronic coronary disease 14 (32.6) 
• Diabetes mellitus 17 (39.5) 
• Atrial fibrillation/flutter 29 (67.4) 
• COPD/Asthma 6 (14.0) 
• Chronic kidney disease 17 (39.5) 
• PCI 16 (37.2) 
• Pacemaker 5 (11.6) 
Renal function data and diuretic response  
• Urea at admission (mg/dL)  57 (3.8 – 8.4) 
• Urea at discharge (mg/dL) 75 (5.4 – 11.3) 
• Creatinine at admission (mg/dL) 1.21 ± 0.53 
• Creatinine at discharge (mg/dL) 1.11 (0.80 – 1.86) 
• Cystatin-C at admission (mg/dL) 1.65 ± 0.58 
• Cystatin-C at discharge (mg/dL) 1.77 ± 0.74 
• eGFR at admission (CKD-EPI- Creatinine) 52.4 (37.3 – 76.6) 
• eGFR at discharge (CKD-EPI- Creatinine) 51.4 (29.3 – 66.8) 
• Uric acid (mg/dL) 7.37 ± 2.69 
• Potassium (mEq/L) 4.19 ± 0.66 
• KIM-1 at admission (ng/mL) 337 (129 – 602) 
WRF at discharge (n[%])  
• Defined as increase in creatinine ≥ 0.3 mg/dL 7 (17.9) 
Surrogate congestion markers  
• CCS at admission (points) 5.5 (4.2 – 6.0) 
• IAP at baseline (mmHg) 14.7 ± 3.9 
• IAP at 72 hours (mmHg) 12.2 ± 4.2 
• IAP decrease (%) -15 (-30.0 – 0.0) 
• IVC diameter at admission (mm) 21.9 ± 6.6 
• IVC diameter at 72 hours (mm) 19.4 (16.7 – 22.7) 
• NT-proBNP at admission (pg/mL) 3780 (2306 – 8929) 
• CA125 at admission (U/mL) 44.3 (22.8 – 116.0) 
• TBW at admission (L) 41.7 ± 10.0 
• TBW at 72 h (L) 39.3 ± 10.1 
• TEW at admission (L) 21.8 ± 6.5 
• TEW at 72 h (L) 21.7 ± 6.3 
ACEi: Angiotensin-converting-enzyme inhibitor; ARBs: Angiotensine recepctor blockers; BMI: Body mass index; 
b.p.m.: beats per minute; CA 125: Carbohydrate antigen 125; CCS: Composite congestion score; COPD: Chronic 
obstructive pulmonary disease; DBP: Diastolic blood pressure; eGFR: Estimated-glomerular filtration rate;  HF: 
Heart failure ; HR: Heart rate; IAP: Intraabdominal Pressure; IVC: Inferior vena cava; KIM-1: Kidney injury 
molecule 1;    LVEF: Left ventricular ejection fraction; MRA: Mineraloid receptor antagonists; NT-proBNP: amino 
terminal fragment of brain natriuretic peptide;   PASP:  Pulmonary artery systolic pressure; PCI: Percutaneous 
coronary intervention. SBP: Systolic blood pressure; TAPSE: Trycuspidic annulus systolic excursion. TBW: Total 








Table S2: Baseline characteristics according to the presence of chronic kidney disease at admission (CKD-EPI < 60mL/min/1.73m2) 
 
Variable eGFR ≥ 60 mL/min eGFR < 60 mL/min P-value 
Total (n[%]) 26 (40.0) 39 (60.0)  
Age (years) 75.8 ± 10.5 81.9 ± 7.2 0.015 
Males (n[%]) 11 (16.9) 18 (27.7) 0.760 
BMI (Kg/m2) 32.0 ± 5.7 27.9 ± 5.0 0.005 
Weight (Kg) 84.2 (72.7 – 98.3) 75.7 (65.3 – 81.7) 0.009 
SBP at admission (mmHg) 131.0 ± 20.0 136.2 ± 21.7 0.412 
DBP at admission (mmHg) 75.9 ± 15.5 77.1 ± 12.6 0.722 
HR (B.p.m.) 82.6 ± 13.6 79.3 ± 18.1 0.438 
NYHA (n[%]):   0.075 
• I 5 (7.7) 6 (9.2)  
• II 18 (27.7) 17 (26.2)  
• III 3 (4.5) 14 (21.5)  
• IV 0 (0.0) 2 (3.1)  
HF treatment (n[%])    
• ACEi/ARBs 17 (26.2) 27 (41.5) 0.745 
• B-blockers 15 (23.1) 22 (33.8) 0.919 
• MRB 10 (15.4) 6 (9.2) 0.034 
• Loop diuretics 17 (26.2) 31 (47.7) 0.205 
Commorbidities (n[%]):    
• HF admissions 17 (26.2) 24 (36.9) 0.753 
• Hypertension 22 (33.8) 31 (47.7) 0.602 
• Dislipemia 11 (16.9) 25 (38.9) 0.083 
• Chronic coronary disease 7 (10.8) 12 (18.5) 0.738 
• Diabetes mellitus 10 (15.4) 17 (26.2) 0.681 
• Atrial fibrillation/flutter 20 (30.8) 23 (35.4) 0.134 
• COPD/Asthma 4 (6.2) 5 (7.7) 0.769 
• Chronic kidney disease 2 (3.1) 19 (29.2) 0.001 
• PCI 10 (15.4) 13 (20.0) 0.672 
• Pacemaker 2 (3.1) 5 (7.7) 0.513 
Echographic variables    
• LVEF (%) 48.0 ± 14.6 50.1 ± 15.7 0.630 
• IVC diameter (mm) 21.9 ± 6.9 21.1 ± 6.1 0.604 
• IVC colapsability (%) 32.0 (12.1 – 48.0) 38.1 (16.9 – 40.0) 0.603 
Clinical variables    
• CCS (points) 5.0 (3.0 – 6.0) 5.0 (4.0 – 6.0) 0.599 
• Mean stay (days) 8.0 (5.7 – 10.0) 8.0 (6.0 – 14.2) 0.592 
• IAP (mmHg) 15.6 ± 4.7 14.9 ± 4.1 0.613 
• IAP at 72 hours 
(mmHg) 
12.5 ± 3.2 12.1 ± 4.7 0.791 
• Urea (mg/dL) 40 (29 – 54) 64 (55 – 101) <0.001 
• Creatinine (mg/dL) 0.79 (0.65 – 0.91) 1.38 (1.10 – 1.76) <0.001 
• Cystatin C (mg/L) 1.1 (0.78 – 1.35) 1.74 (1.39 – 2.15) <0.001 
• Uric acid (mg/dL) 7.0 ± 2.9 8.0 ± 2.1 0.123 
• Total proteins (g/dL) 6.4 ± 0.3 6.6 ± 0.8 0.422 
• Total cholesterol 
(mg/dL) 
135.8 ± 24.0 137.1 ± 35.6 0.877 
• Triglicerides (mg/dL) 81.0 (65.5 – 107.0) 88.0 (71.0 – 115.2) 0.382 
• Albnmin (mg/dL) 3.16 ± 037 3.06 ± 0.40 0.348 
• Sodium (mEq/L) 140.8 (139.4 – 143.6) 140.6 (138.5 – 143.6) 0.746 
• Potassium (mEq/L) 3.9 ± 0.5 4.3 ± 0.5 0.004 
• Chloride (mEq/L) 97.5 ± 4.1 98.9 ± 5.3 0.270 
• Bicarbonate (mmol/L) 26.1 (24.6 – 31.2) 22.9 (21.6 – 27.9) 0.018 
• Hemoglobin (g/L) 12.3 ± 2.0 11.5 ± 1.1 0.031 
• Hematocritum (%) 37.8 ± 5.7 35.4 ± 3.1 0.058 
Surrogate congestion markers    
• NT-proBNP (pg/mL) 2476 (1662 – 3474) 6876 (3221 – 12850) <0.001 
• CA125 (U/mL) 36.1 (15.0 – 62.2) 49.3 (29.3 – 103.6) 0.028 
Bioelectrical impedance vector 
analysis 
   
• TBW (L) 44.4 ± 11.7 41.4 ± 8.6 0.233 
• TEW (L) 26.2 ± 11.2 23.3 ± 6.8 0.209 
 
ACEi: Angiotensin-converting-enzyme inhibitor; AKI: Acute kidney injure; ARBs: Angiotensine recepctor blockers;  BMI: Body mass index; 
b.p.m.: beats per minute; CA 125: Carbohydrate antigen 125; CCS: Composite congestion score; COPD: Chronic obstructive pulmonary 
disease; DBP: Diastolic blood pressure; e-GFR: Glomerular filtration rate; HF: Heart failure ; HR: Heart rate; IAP: Intraabdominal Pressure; 
IVC: Inferior vena cava;  LVEF: Left ventricular ejection fraction; MRB: Mineraloid receptor blockers; NT-proBNP: amino terminal fragment 
of brain natriuretic peptide; PCI: Percutaneous coronary intervention; TBW: Total body water; TEW: Total Extracellular water. 
 
Table S3: Baseline characteristics according to the presence of worsening renal function at discharge (defined as the increase of ≥ 0.3 mg/dL 
of creatinine).  
Variable NOT WRF  WRF P-value 
Total (n[%]) 32 (82.1) 7 (17.9)  
Age (years) 79.6 ± 9.4 83.4 ± 3.7 0.304 
Females (n[%]) 20 (62.5) 4 (57.1) 0.792 
BMI (Kgs/m2) 30.8 ± 6.4 27.3 ± 6.9 0.202 
Weight (Kg) 78.8 (67.7 – 86.6) 71.0 (61.6 – 86.0) 0.487 
SBP at admission (mmHg) 137.9 ± 20.8 130.0 ±27.0 0.395 
DBP at admission (mmHg) 77.5 ±13.4 79.7 ± 10.1 0.698 
HR (B.p.m.) 72.5 (65.2 – 95.5) 85.0 (71.0 – 102.0) 0.389 
NYHA (n[%]):   0.107 
• I 6 (18.8) 0 (0.0)  
• II 18 (56.3) 2 (28.6)  
• III 7 (21.9) 4 (57.1)  
• IV 1 (3.1) 1 (14.3)  
HF treatment (n[%])    
• ACEi/ARBs 23 (71.9) 5 (71,4) 0.987 
• B-blockers 19 (59.4) 2 (28.6) 0.139 
• MRB 4 (12.5) 3 (42.9) 0.058 
• Loop diuretics 22 (68.8) 6 (85.7) 0.366 
Commorbidities (n[%]):    
• HF admissions 17 (53.1) 5 (71.4) 0.376 
• Hypertension 26 (81.3) 6 (85.7) 0.780 
• Dislipemia 16 (50.0) 4 (57.1) 0.732 
• Chronic coronary disease 11 (34.4) 3 (42.9) 0.672 
• Diabetes mellitus 11 (34.4) 3 (42.9) 0.672 
• Atrial fibrillation/flutter 22 (68.8) 5 (71.4) 0.889 
• COPD/Asthma 3 (9.4) 3 (42.9) 0.026 
• Chronic kidney disease 11 (34.4) 6 (85.7) 0.013 
• PCI 13 (40.6) 2 (28.6) 0.553 
• Pacemaker 4 (12.5) 1 (14.3) 0.898 
Echographic variables    
• LVEF (%) 49.3 ± 14.5 47.6 ± 20.1 0.805 
• IVC diameter (mm) 21.3 ± 6.0 24.0 ± 8.1 0.351 
• IVC colapsability (%) 34.5 (17.0 – 75.9) 27.3 (6.3 – 49.7) 0.711 
Clinical variables    
• CCS (points) 6 (5 – 6) 5 (4- 6) 0.699 
• IAP (mmHg) 14.8 ± 4.2 14.6 ± 3.7 0.570 
• IAP at 72 hours 
(mmHg) 
12.3 ± 4.6 11.8 ± 3.7 0.814 
• Urea (mg/dL) 52 (36 - 63) 100 (64 – 110) 0.006 
• Creatinine (mg/dL) 1.03 (0.78 – 1.28) 1.67 (1.29 – 1.96) 0.017 
• Cystatin C (mg/dL) 1.51 ± 0.53 2.17 ± 0.69 0.013 
• KIM-1 (ng/mL) 273 (109 – 457) 602 (129 – 961) 0.107 
• Uric acid (mg/dL) 7.06 ± 2.7 8.2 ± 1.6 0.261 
• Total proteins (g/dL) 6.4 ± 0.5 6.1 ± 0.2 0.326 
• Total cholesterol 
(mg/dL) 
137.8 ± 33.0 124.4 ± 24.4 0.321 
• Triglicerides (mg/dL) 96.1 ± 36.6 83.1 ± 12.6 0.354 
• Albnmin (mg/dL) 3.09 ± 0.40 2.86 ± 0.15 0.676 
• Sodium (mEq/L) 140 ± 4 142 ± 4 0.321 
• Potassium (mEq/L) 4.08 ± 0.62 4.68 ± 0.73 0.034 
• Chloride (mEq/L) 98.2 ± 5.3 100.4 ± 3.2 0.304 
• Bicarbonate (mmol/L) 25.4 ± 3.9 24.2 ± 4.5 0.462 
• Hemoglobin (g/L) 11.8 ± 1.7 11.7 ± 0.9 0.893 
• Hematocritum (%) 36.6 ± 5.5 36.7 ± 3.6 0.980 
Surrogate congestion markers    
• NT-proBNP (pg/mL) 3092 (2158 – 6345) 8929 (7041 – 32700) 0.004 
• CA125 (U/mL) 41.2 (17.0 – 75.7) 60.8 (37.6 – 417.2) 0.194 
Bioelectrical impedance vector 
analysis 
   
• TBW (L) 41.6 ± 9..6 43.5 ± 12.3 0.672 
• TEW (L) 22.1 ± 7.0 23.0 ± 8.6 0.794 
 
ACEi: Angiotensin-converting-enzyme inhibitor; AKI: Acute kidney injure; ARBs: Angiotensine recepctor blockers;  BMI: Body mass index; 
b.p.m.: beats per minute; CA 125: Carbohydrate antigen 125; CCS: Composite congestion score; COPD: Chronic obstructive pulmonary 
disease; DBP: Diastolic blood pressure; e-GFR: Glomerular filtration rate; HF: Heart failure ; HR: Heart rate; IAP: Intraabdominal Pressure; 
IVC: Inferior vena cava;  LVEF: Left ventricular ejection fraction; MRB: Mineraloid receptor blockers; NT-proBNP: amino terminal fragment 
of brain natriuretic peptide; PCI: Percutaneous coronary intervention; TBW: Total body water; TEW: Total Extracellular water. 
 
